Filter Your Search
One of the more exciting developments in neurofibromatosis (NF) research today is the success of the MEK inhibitor clinical trial, in which over 70% of participants are seeing reductions of 20-55% in the size of their inoperable plexiform neurofibromas. The research surrounding this particular drug, selumetinib, is being prepared for submission to the FDA, and indicators are that it could become the first-ever approved drug for NF.
The Neurofibromatosis Therapeutic Acceleration Program (NTAP) is now accepting applications for the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. The Collins Scholars program brings together a community of exceptionally well-trained clinician scientists who will be leaders in the field of NF1 research.
The 2019 New York Stem Cell Foundation Early Career Investigator Award RFAs have been released, which are open to early career investigators around the world. These awards provide $1.5 million over 5 years.
Children’s Tumor Foundation Research Advances Understanding of Brain Tumors
Treatment for low-grade gliomas in patients living with neurofibromatosis type 1 are now one step closer thanks to recent research discoveries initiated and funded by the Children’s Tumor Foundation.
Your ongoing support has allowed us to take huge steps forward in 2018 in the fight against NF. Your efforts and contributions have been instrumental in advancing neurofibromatosis research, providing hope for the millions worldwide who live with NF, and bringing us ever closer to our shared goal of ending NF forever.